| Year |
Citation |
Score |
| 2022 |
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CWM, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, ... ... Khodadoust MS, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. PMID 36584673 DOI: 10.1016/j.ccell.2022.12.005 |
0.306 |
|
| 2020 |
Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, Shizuru J, Muffly L, Meyer E, Negrin RS, Wang E, Almazan T, Million L, Khodadoust M, Li S, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances. 4: 4474-4482. PMID 32941647 DOI: 10.1182/Bloodadvances.2020001627 |
0.313 |
|
| 2020 |
Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine. 217. PMID 32558897 DOI: 10.1084/Jem.20191712 |
0.36 |
|
| 2020 |
Hoffmann JC, Atwater SK, Hong E, Kumar J, Khodadoust M, Kim Y, Ohgami RS. A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. The American Journal of Dermatopathology. 42: 389-396. PMID 32433315 DOI: 10.1097/Dad.0000000000001637 |
0.361 |
|
| 2020 |
Schürch CM, Phillips DJ, Gutierrez BR, Matusiak M, Bhate SS, Barlow GL, Fling SP, Ramchurren N, Pierce RH, Cheever MA, Khodadoust MS, West R, Kim YH, Nolan GP. Abstract 6669: Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma Immunology. 80: 6669-6669. DOI: 10.1158/1538-7445.Am2020-6669 |
0.428 |
|
| 2019 |
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. The Lancet. Oncology. PMID 31253572 DOI: 10.1016/S1470-2045(19)30320-1 |
0.378 |
|
| 2019 |
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nature Biotechnology. PMID 31061481 DOI: 10.1038/S41587-019-0114-2 |
0.336 |
|
| 2019 |
Obeid JP, Gutkin PM, Lewis J, Skinner L, Wang EB, Khodadoust MS, Kim YH, Weng WK, Hoppe RT, Hiniker SM. Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs. Practical Radiation Oncology. PMID 30836188 DOI: 10.1016/J.Prro.2019.02.016 |
0.31 |
|
| 2019 |
Wagar LE, Sworder B, Khodadoust MS, Davis MM, Alizadeh AA. Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment Blood. 134: 2799-2799. DOI: 10.1182/Blood-2019-131192 |
0.372 |
|
| 2019 |
Shree T, Khodadoust MS, Czerwinski DK, Frank MJ, Hong WX, Greenstein R, Long SR, Martin B, Levy R. A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma Blood. 134: 2825-2825. DOI: 10.1182/Blood-2019-129661 |
0.405 |
|
| 2019 |
Kathuria KR, Chen B, Khodadoust MS, Olsson N, Davis MM, Elias JE, Levy R, Altman RB, Alizadeh AA. Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation Blood. 134: 84-84. DOI: 10.1182/Blood-2019-129334 |
0.345 |
|
| 2019 |
Sworder B, Kurtz DM, Macaulay C, Frank MJ, Alig S, Garofalo A, Sahaf B, Esfahani MS, Spiegel JY, Oak J, Beygi S, Jin MC, Chabon JJ, Khodadoust MS, Majzner RG, et al. Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy Blood. 134: 550-550. DOI: 10.1182/Blood-2019-129015 |
0.401 |
|
| 2019 |
Ng PP, Mobasher M, Yeung KS, Hotson AN, Hill CM, Madriaga A, Dao-Pick TP, Verner E, Radeski D, Khodadoust MS, Kim YH, Miller RA, Buggy JJ, Janc JW. Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells Blood. 134: 1571-1571. DOI: 10.1182/Blood-2019-127338 |
0.415 |
|
| 2019 |
Schuerch CM, Phillips DJ, Bhate SS, Barlow GL, Fling SP, Ramchurren N, Pierce R, Cheever MA, Khodadoust MS, Kim YH, Nolan GP. Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging Blood. 134: 1521-1521. DOI: 10.1182/Blood-2019-125315 |
0.383 |
|
| 2019 |
Mobasher M, Miller RA, Janc JW, Kwei L, Buggy JJ, Luciano G, Mohammady A, Kim WS, Kim YH, Khodadoust MS, Horwitz SM, Radeski D. A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma Blood. 134: 4030-4030. DOI: 10.1182/Blood-2019-124958 |
0.324 |
|
| 2019 |
Shree T, Khodadoust MS, Czerwinski D, Frank MJ, Hong WX, Greenstein R, Guo S, Long S, Martin BA, Levy R. Abstract CT133: Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct133 |
0.414 |
|
| 2019 |
Horwitz S, Foss F, Porcu P, Moskowitz A, Mehta-Shah N, Jacobsen E, Khodadoust M, Kim Y, Weinstock D, Lustgarten S, Baglio M, Youssoufian H, Brammer J. Duvelisib, an oral dual PI3K-δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T-cell lymphoma: rationale for the phase 2 PRIMO trial Hematological Oncology. 37: 65-66. DOI: 10.1002/Hon.33_2629 |
0.338 |
|
| 2019 |
Buggy J, Ng P, Janc J, Hotson A, Hill C, Thamm D, Kim Y, Khodadoust M, Mobasher M, Miller R. A SELECTIVE AND COVALENT INHIBITOR OF ITK BLOCKS TCR SIGNALING, INHIBITS PROLIFERATION OF HUMAN SÉZARY CELLS IN VITRO, AND INDUCES TUMOR REGRESSION IN DOGS WITH T-CELL LYMPHOMA Hematological Oncology. 37: 319-320. DOI: 10.1002/Hon.129_2630 |
0.366 |
|
| 2019 |
Mobasher M, Miller R, Janc J, Kwei L, Barker C, Mohammady A, Luciano G, Radeski D, Kim Y, Khodadoust M, Horwitz S. A Phase 1/1B Dose-Escalation Trial Evaluating Cpi-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Patients With Relapsed/Refractory T-Cell Lymphoma Hematological Oncology. 37: 563-564. DOI: 10.1002/Hon.11_2632 |
0.374 |
|
| 2018 |
Torrey H, Khodadoust M, Tran L, Baum D, Defusco A, Kim YH, Faustman DL. Targeted killing of TNFR2-expressing tumor cells and T by TNFR2 antagonistic antibodies in advanced Sézary syndrome. Leukemia. PMID 30356161 DOI: 10.1038/S41375-018-0292-9 |
0.366 |
|
| 2018 |
Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018785246. PMID 30125215 DOI: 10.1200/Jco.2018.78.5246 |
0.32 |
|
| 2018 |
Satpathy AT, Saligrama N, Buenrostro JD, Wei Y, Wu B, Rubin AJ, Granja JM, Lareau CA, Li R, Qi Y, Parker KR, Mumbach MR, Serratelli WS, Gennert DG, Schep AN, ... ... Khodadoust MS, et al. Transcript-indexed ATAC-seq for precision immune profiling. Nature Medicine. PMID 29686426 DOI: 10.1038/S41591-018-0008-8 |
0.376 |
|
| 2018 |
Olsson N, Schultz LM, Zhang L, Khodadoust MS, Narayan R, Czerwinski DK, Levy R, Elias JE. T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins. Proteomics. PMID 29493099 DOI: 10.1002/Pmic.201700410 |
0.379 |
|
| 2018 |
Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods in Molecular Biology (Clifton, N.J.). 1711: 243-259. PMID 29344893 DOI: 10.1007/978-1-4939-7493-1_12 |
0.316 |
|
| 2018 |
Horwitz SM, Feldman TA, Hess BT, Khodadoust MS, Kim YH, Munoz J, Patel MR, Phillips TJ, Smith SD, Smith SM, Wilcox RA, Steele A, Pandey A, Birrell MR, Leeds JM, et al. The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma Blood. 132: 1001-1001. DOI: 10.1182/Blood-2018-99-119944 |
0.34 |
|
| 2018 |
Czerwinski DK, Frank MJ, Shree T, Khodadoust MS, Long SR, Levy R. Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma Blood. 132: 1612-1612. DOI: 10.1182/Blood-2018-99-119931 |
0.407 |
|
| 2018 |
Bagot M, Porcu P, William BM, Battistella M, Vermeer M, Whittaker S, Ram-Wolff C, Khodadoust MS, Sicard H, Azim HA, Kim YH. IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial Blood. 132: 684-684. DOI: 10.1182/Blood-2018-99-118021 |
0.362 |
|
| 2018 |
Khodadoust MS, Rook A, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, Shanbhag S, Sokol L, Fling SP, Li S, Davis A, Fong S, Kim J, Yang Y, Yearley JH, et al. Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study Blood. 132: 2896-2896. DOI: 10.1182/Blood-2018-99-117244 |
0.305 |
|
| 2018 |
Torrey H, Defusco A, Baum D, Rhabar Z, Khodadoust M, Kim YH, Faustman DL. Abstract B18: Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-B18 |
0.4 |
|
| 2018 |
Faustman DL, Torrey H, Khodadoust M, Defusco A, Baum D, Rahbar Z, Kim YH. Abstract 1790: TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma Immunology. DOI: 10.1158/1538-7445.Am2018-1790 |
0.361 |
|
| 2018 |
Bagot M, Porcu P, William B, Vermeer M, Whittaker S, Wolff CR, Khodadoust M, Battistella M, Paiva C, Sicard H, Azim H, Kim Y. IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study European Journal of Cancer. 101. DOI: 10.1016/J.Ejca.2018.07.282 |
0.342 |
|
| 2017 |
Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. PMID 28899864 DOI: 10.1158/2159-8290.Cd-17-0716 |
0.301 |
|
| 2017 |
Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. PMID 28329770 DOI: 10.1038/Nature21433 |
0.326 |
|
| 2017 |
Kurtz DM, Scherer F, Jin M, Soo J, Craig A, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust M, Advani RH, Levy R, et al. Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma Blood. 130: 826-826. DOI: 10.1182/Blood.V130.Suppl_1.826.826 |
0.311 |
|
| 2017 |
Moskowitz AJ, Koch R, Mehta-Shah N, Myskowski P, Kheterpal M, Dogan A, Davey T, Galasso N, Evan M, Shah M, Ganesan N, Lubin L, Kim YH, Khodadoust M, Almazan T, et al. In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma Blood. 130: 819-819. DOI: 10.1182/Blood.V130.Suppl_1.819.819 |
0.347 |
|
| 2017 |
Frank M, Khodadoust M, Chu M, Kohrt H, Advani R, Alizadeh A, Reddy S, Maeda L, Gupta N, Laport G, Meyer E, Miklos D, Negrin R, Rezvani A, Weng W, et al. PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA Hematological Oncology. 35: 207-208. DOI: 10.1002/Hon.2438_72 |
0.358 |
|
| 2017 |
Bagot M, Porcu P, Ram-Wolff C, Khodadoust M, Basem W, Battistella M, Marie-Cardine A, Vermeer M, Mathieu S, Whittaker S, Duvic M, Bensussan A, Paturel C, Bonnafous C, Thonnart N, et al. Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results Hematological Oncology. 35: 48-49. DOI: 10.1002/Hon.2437_31 |
0.34 |
|
| 2016 |
Kurtz DM, Scherer F, Newman AM, Craig AF, Khodadoust MS, Lovejoy AF, Klass DM, Chabon JJ, Glover C, Zhou L, Liu CL, Gupta NK, Maeda LS, Advani RH, Levy R, et al. Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. Journal of Clinical Oncology. 34: 7511-7511. DOI: 10.1200/Jco.2016.34.15_Suppl.7511 |
0.311 |
|
| 2016 |
Kim YH, Hoppe RT, Rook AH, Maity A, Geskin LJ, Horowitz DP, Finnegan G, Khodadoust M, Weng W, Lares A, Hong EKJ, Buchanan M, Ma V, Kha H, Lawrence CE, et al. A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT) Blood. 128: 4165-4165. DOI: 10.1182/Blood.V128.22.4165.4165 |
0.311 |
|
| 2016 |
Levy R, Reagan PM, Friedberg JW, Bartlett NL, Gordon LI, Leung A, Peterkin J, Xing B, Coffman R, Janssen R, Candia A, Khodadoust M, Frank MJ, Long SR, Czerwinski DK, et al. SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial Blood. 128: 2974-2974. DOI: 10.1182/Blood.V128.22.2974.2974 |
0.35 |
|
| 2016 |
Czerwinski DK, Long SR, Khodadoust M, Frank MJ, Kardosh A, Okada A, Robinson S, Levy R. Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients Blood. 128: 2947-2947. DOI: 10.1182/Blood.V128.22.2947.2947 |
0.437 |
|
| 2016 |
Bagot M, Porcu P, Ram-Wolff C, Khodadoust M, Battistella M, Marie-Cardine A, Mathieu S, Vermeer MH, Whittaker S, Duvic M, Bensussan A, Paturel C, Bonnafous C, Thonnart N, Widemann A, et al. First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results Blood. 128: 1826-1826. DOI: 10.1182/Blood.V128.22.1826.1826 |
0.343 |
|
| 2016 |
Khodadoust M, Rook AH, Porcu P, Foss FM, Moskowitz AJ, Shustov AR, Shanbhag S, Sokol L, Shine R, Fling SP, Li S, Rabhar Z, Kim J, Yang Y, Yearley J, et al. Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study Blood. 128: 181-181. DOI: 10.1182/Blood.V128.22.181.181 |
0.334 |
|
| 2016 |
Levy R, Bartlett N, Friedberg J, Reagan P, Gordon L, Bergman C, Coffman R, Janssen R, Candia A, Khodadoust M, Frank M, Long S, Czerwinski D, Chu M, Kohrt H. Abstract CT047: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct047 |
0.362 |
|
| 2015 |
Khodadoust MS, Chu MP, Czerwinski D, McDonald K, Long S, Kohrt HE, Hoppe RT, Advani RH, Lowsky R, Levy R. Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. Journal of Clinical Oncology. 33: TPS8604-TPS8604. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps8604 |
0.319 |
|
| 2015 |
Kurtz DM, Scherer F, Green MR, Khodadoust MS, Klass DM, Zhou L, Krishnan R, Glover C, Liu CL, Kong KA, Faham M, Levy R, Diehn M, Alizadeh AA. Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL. Journal of Clinical Oncology. 33: 8570-8570. DOI: 10.1200/Jco.2015.33.15_Suppl.8570 |
0.335 |
|
| 2015 |
Schultz LM, Olsson N, Khodadoust M, Narayan R, Sagiv-Barfi I, Elias J, Levy R. T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC Blood. 126: 2228-2228. DOI: 10.1182/Blood.V126.23.2228.2228 |
0.378 |
|
| 2015 |
Czerwinski DK, Long SR, Khodadoust M, Frank MJ, Chu MP, Okada A, McDonald KA, Kohrt HE, Bartlett NL, Reagan PM, Friedberg JW, Gordon LI, Coffman R, Janssen R, Levy R. Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN Blood. 126: 1539-1539. DOI: 10.1182/Blood.V126.23.1539.1539 |
0.427 |
|
| 2015 |
Chu MP, Brody J, Kohrt HE, Frank MJ, Khodadoust M, Reddy S, Advani RH, Gupta NK, Laport G, Maeda LS, Meyer E, Miklos DB, Negrin R, Rezvani AR, Weng W, et al. Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis Blood. 126: 1536-1536. DOI: 10.1182/Blood.V126.23.1536.1536 |
0.379 |
|
| 2011 |
Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS, Chinnaiyan AM, Luger K, Erhardt S, Schneider R, Markovitz DM. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes & Development. 25: 673-8. PMID 21460035 DOI: 10.1101/Gad.2036411 |
0.593 |
|
| 2011 |
Kappes F, Khodadoust MS, Yu L, Kim DS, Fullen DR, Markovitz DM, Ma L. DEK expression in melanocytic lesions. Human Pathology. 42: 932-8. PMID 21316078 DOI: 10.1016/J.Humpath.2010.10.022 |
0.56 |
|
| 2009 |
Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Research. 69: 6405-13. PMID 19679545 DOI: 10.1158/0008-5472.Can-09-1063 |
0.619 |
|
| 2008 |
Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A, Markovitz DM, Ferrando-May E. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. Molecular and Cellular Biology. 28: 3245-57. PMID 18332104 DOI: 10.1128/Mcb.01921-07 |
0.611 |
|
| 2006 |
Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, Kappes F, Ruth JH, Koch A, Glass D, Petruzzelli L, Adams BS, Markovitz DM. The DEK nuclear autoantigen is a secreted chemotactic factor. Molecular and Cellular Biology. 26: 9484-96. PMID 17030615 DOI: 10.1128/Mcb.01030-06 |
0.632 |
|
| 2005 |
Cleary J, Sitwala KV, Khodadoust MS, Kwok RP, Mor-Vaknin N, Cebrat M, Cole PA, Markovitz DM. p300/CBP-associated factor drives DEK into interchromatin granule clusters. The Journal of Biological Chemistry. 280: 31760-7. PMID 15987677 DOI: 10.1074/Jbc.M500884200 |
0.713 |
|
| Show low-probability matches. |